

Curriculum Vitae
Lars Martin Lagging, M.D. PhD

Born: September 27, 1965 in Göteborg, Sweden

Office Address:

Department of Infectious Medicine/Virology
University of Gothenburg
Guldhedsgatan 10B
SE-413 46 Göteborg
Sweden

Telephone: +46-31-342 46 58
FAX: +46-31-41 12 56
Email: martin.lagging@medfak.gu.se

Education and Training:

- College: Sept. 1982-May 1983: Johns Hopkins University, Baltimore, Maryland, USA.
- Medical School: Aug. 1983-Jan 1989: Karolinska Institute School of Medicine, Stockholm, Sweden.
- Residency (AT): June 1989-Feb 1991: Länssjukhuset Ryhov, Jönköping, Sweden.
- March 1, 1991: Licensed Physician in Sweden.
- Fellowship in Infectious Diseases: April 1992-June 1995: Division of Infectious Diseases, Saint Louis University Medical Center, St. Louis, Missouri, USA.
- October 22, 1997: Licensed Specialist in Infectious Diseases in Sweden.
- May 6, 2002: Licensed Specialist in Clinical Virology in Sweden.

Ph.D. Degree: 2002 Institutions: Departments of Virology and Infectious Diseases, Faculty of Medicine, Göteborg University, Göteborg Sweden.

Associate Professor in Clinical Virology: April 18, 2007-July 31, 2014

Professor in Clinical Virology: August 1, 2014

Vice-Dean for Third Cycle (PhD) Studies at Sahlgrenska Academy: November 1, 2019

Current Position: From August 1, 2014 Professor in Clinical Virology at the Department of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg as well as Vice Director of Studies (Studierektor) for the Institute of Biomedicine. Additionally employed 30% as a Medical Physician at the Department of Clinical Virology (4 days per week), and Department of Infectious Diseases (1 day per week), Sahlgrenska University Hospital, Göteborg, Sweden.

Clinical Trials:

- Investigator in DITTO-HCV trial 2001-2003
- Steering committee in NORDynamIC trial 2004-
- Steering committee in RelapC trial 2006-
- Principal Investigator in the RibaC trial 2010-

GCP (Good Clinical Practice) Certification: April 18-19, 2007: Participated in an IPULS certified GCP course held by the Swedish Academy of Pharmaceutical Sciences (IPULS-nr: 2007023).

Former Appointments:

- June 1989-Feb 1991: Residency (AT), Länssjukhuset Ryhov, Jönköping, Sweden
- July 1991-Sept 1991: Department of Infectious Diseases, Länssjukhuset Ryhov, Jönköping, Sweden.
- Oct 1991-March 1992: Department of Internal Medicine, Länssjukhuset Ryhov, Jönköping, Sweden.
- April 1992-June 1995: Division of Infectious Diseases, Saint Louis University Medical Center, St. Louis, Missouri, USA.
- September 1995-April 1999: Department of Infectious Diseases, Sahlgrenska University Hospital, Göteborg, Sweden.
- From May 1999 until July 31, 2014: Medical Physician (Överläkare) at the Department of Clinical Virology (4 days per week), and Department of Infectious Diseases (1 day per week), Sahlgrenska University Hospital, Göteborg, Sweden.

Current major funding:

- Vetenskapsrådet since 2009 (Diariennr 2008:2427), renewed 2011 (Diariennr 2011:3821) and 2017 (Diariennr 2017-00855): 800 000 SEK per year and employment as a researcher (50%) 850 000 SEK per year; Project title: Translational research in hepatitis C virus (HCV) and other microbial infections: Impact of inosine triphosphate pyrophosphatase (ITPase) activity on ribavirin-induced mutagenesis.
- ALF/LUA funds since 2011, renewed 2017 (Diariennr ALFGBG-717711): 500 000 SEK per year; Project title: Translationell forskning på hepatit C virus (HCV) och andra mikrobiella infektioner: Påverkan av inosine trifosfat pyrofosfatas (ITPas) aktivitet på ribavirin inducerad mutagenes.
- Regionala FoU-medel Västra Götalandsregionen (Diariennr VGFOUREG-837522) 220 000 SEK per year
- FoU Laboratoriemedicin, Sahlgrenska Universitetssjukhuset. 200 000 SEK per year

Awards:

- 1998 Pharmacia & Upjohn Research Award
- 2005 AASLD President's Choice Award
- 2007 AASLD President's Choice Award

Member of the evaluation panel of the Swedish Research Council (Vetenskapsrådet) for Medicine and Health 2015 and 2016

Publications:

(H-index 35, citations 6250, full publication list available at <https://scholar.google.se/citations?user=p-uN7ToAAAAJ&hl=sv>)

2020

- 1) Katharina Büsch, Fredrik Hansson, Michelle Holton, **Martin Lagging**, Johan Westin, Jan Kövamees, Matti Sällberg, Jonas Söderholm. Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. *BMJ Open*. 2020 Sep 2;10(9):e035996.
- 2) Jesper Waldenström, Kristina Nyström, Staffan Nilsson, Gunnar Norkrans, Magdalena Ydreborg, Nina Langeland, Kristine Mørch, Johan Westin, **Martin Lagging**. The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. *PLoS One* 2020 Aug 21;15(8):e0237840.

2019

- 3) Miriam Karlsson, Helene Norder, Maria Bergström, Per-Ola Park, Marie Karlsson, Rune Wejstål, Åsa Alsiö, Anders Rosemar, **Martin Lagging**, Åsa Mellgren. Hepatitis E Virus Genotype 3 is Associated with Gallstone Related Disease. Accepted for publication in *Scandinavian Journal of Gastroenterology*.
- 4) Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, **Lagging M**, Midgard H, Moghaddam A, Dalgard O. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. *Scand J Gastroenterol*. 2019 Sep 3:1-4.
- 5) Jonas Söderholm, Aylin Yilmaz, Anders Svenningsson, Katharina Büsch, Rune Wejstål, Alma Brolund, Jan Kövamees, Matti Sällberg, **Martin Lagging**, Magnus Gisslén. Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. *J Neurol*. 2019 Sep;266(9):2208-2215.
- 6) Kristina Nyström, Jesper Waldenström, Ka-Wei Tang, and **Martin Lagging**. Ribavirin: pharmacology, multiple modes of action and possible future perspectives. *Future Virology* 2019 14(3), 153–160
- 7) Catarina Skoglund, **Martin Lagging**, Maria Castedal. No need to discontinue hepatitis C virus therapy at the time of liver transplantation. *PLoS One*. 2019 Feb 22;14(2):e0211437. doi: 10.1371/journal.pone.0211437. eCollection 2019.

2018

- 8) Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, Nurmukhametova E, Kozhevnikova G, Gankina N, Zhuravel S, Romanova S, Hyland RH, Lu S, Svarovskaia ES, McNally J, Brainard DM, Ivashkin V, Morozov V, Bakulin I, **Lagging M**, Zhdanov K, Weiland O. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. *Infect Dis (Lond)*. 2018 Nov 30:1-9. doi: 10.1080/23744235.2018.1535186.
- 9) Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, **Lagging M**. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and

Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. *J Virol*. 2018 Sep 12;92(19). pii: e01087-18. doi: 10.1128/JVI.01087-18. Print 2018 Oct 1.

- 10) Aparna Vasanthakumar, Justin W. Davis, Manal Abunimeh, Jonas Söderholm, Jiahong Zha, Emily O. Dumas, Daniel E. Cohen, Jeffrey F. Waring, **Martin Lagging**. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. *PLoS One*. 2018 May 31;13(5):e0198296. doi: 10.1371/journal.pone.0198296. eCollection 2018.
- 11) **Lagging M**, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J; ; for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. *Infect Dis (Lond)*. 2018 Mar 1:1-15. doi: 10.1080/23744235.2018.1445281.

2017

- 12) Waldenström J, **Lagging M**. Ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis. *Aliment Pharmacol Ther*. 2017 Dec;46(11-12):1115-1116. doi: 10.1111/apt.14354.
- 13) Hansen JF, Juul Nielsen M, Nyström K, Leeming DJ, **Lagging M**, Norkrans G, Brehm Christensen P, Karsdal M. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. *Scand J Gastroenterol*. 2017 Oct 25:1-5. doi: 10.1080/00365521.2017.1392596.
- 14) Dalgard O, Weiland O, Noraberg G, Karlsten L, Heggelund L, Färkkilä M, Balslev U, Belard E, Øvrehus A, Skalshei Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, **Lagging M**, Weis N. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. *PLoS One*. 2017 Jul 13;12(7):e0179764. doi: 10.1371/journal.pone.0179764.
- 15) Andréasson K, Waldenström J, Westin J, Norrgren H, Jönsson G, Nyström K, **Lagging M**. Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. *J Hepatol*. 2017 Sep;67(3):649-651. doi: 10.1016/j.jhep.2017.03.043.
- 16) **Lagging M**, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. *Infect Dis (Lond)*. 2017 Aug;49(8):561-575. doi: 10.1080/23744235.2017.1300682.

- 17) Åsa Mellgren, Miriam Karlsson, Marie Karlsson, **Martin Lagging**, Rune Wejstål, Heléne Norder High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection. *J Clin Virol*. 2017 Mar;88:39-45. (**Impact factor 2.6**)

2016

- 18) Grahn A, Bråve A, **Lagging M**, Dotevall L, Ekqvist D, Hammarström H, Karlberg H, Lagerqvist N, Sansone M, Tegnell A, Ulleryd P, Studahl M. Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit. *Open Forum Infect Dis*. 2016 Sep 20;3(4):ofw198. (**Impact factor 1.0**)
- 19) Büsch K, Waldenström J, **Lagging M**, Aleman S, Weiland O, Kövamees J, Duberg AS, Söderholm J. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. *Scand J Gastroenterol*. 2016 Sep 6:1-8. (**Impact factor 2.2**)
- 20) Jesper Waldenström, Johan Westin, Kristina Nyström, Peer Christensen, Olav Dalgard, Martti Färkkilä, Karin Lindahl, Staffan Nilsson, Gunnar Norkrans, Henrik Krarup, Hans Norrgren, Mads Rauning Buhl, Stephan Stenmark, and **Martin Lagging**. Randomized Trial Evaluating The Impact Of Ribavirin Mono-Therapy And Double Dosing On Viral Kinetics, Ribavirin Pharmacokinetics And Anemia In Hepatitis C Virus Genotype 1 Infection. *PLoS One*. 2016 May 11;11(5):e0155142. doi: 10.1371/journal.pone.0155142. (**Impact factor 3.5**)
- 21) **Lagging M**, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN 3rd, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. *J Viral Hepat*. 2016 Feb;23(2):80-8. doi: 10.1111/jvh.12464. (**Impact Factor 4.2**)

2015

- 22) Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnus L, **Lagging M**. Diagnostic performance of five assays for anti-HEV IgG and IgM in a large cohort study. *J Clin Microbiol*. 2015 Dec 9. pii: JCM.02343-15. (**Impact Factor 4.0**)
- 23) **Lagging M**, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Josephson F. Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. *Infect Dis (Lond)*. 2015 Dec 1:1-11. (**Impact Factor 1.4**)
- 24) Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsö Å, Holmström L,

Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, **Lagging M**. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. *Scand J Gastroenterol*. 2015 Sep 29;1-7. (**Impact Factor 2.2**)

25) Waldenström J, Castedal M, Konar J, Karason K, **Lagging M**, Norder H. Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report. *J Med Case Rep*. 2015 Aug 26;9:180. (**Impact Factor 0.7**)

26) Rembeck K, **Lagging M**. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. *Pharmacogenomics*. 2015 Aug 7:1-10. (**Impact Factor 2.7**)

27) Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, **Lagging M**, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *The Lancet*. 2015 Mar 21;385(9973):1075-86. (**Impact Factor 59.1**)

2014

28) Waldenström J, Nyström K, **Lagging M**. Do variations in the ITPA gene determine the risk of hepatitis C virus relapse? *Future Microbiol*. 2014;9(9):1009-12. (**Impact Factor 3.6**)

29) Persson L, Longhi S, Enarsson J, Andersen O, Haghigi S, Nilsson S, **Lagging M**, Johansson M, Bergström T. Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. *J Clin Virol*. 2014 Sep;61(1):107-12. (**Impact Factor 2.6**)

30) Ydreborg M, Lisovskaja V, **Lagging M**, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. *PLoS One*. 2014 Apr 3;9(4):e93601. (**Impact Factor 3.5**)

31) Jerkeman A, Norkrans G, Lidman C, Westin J, **Lagging M**, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P. Treatment for chronic hepatitis C in a cohort of

opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy. *Eur J Gastroenterol Hepatol*. 2014 May;26(5):523-31. **(Impact Factor 2.1)**

- 32) **Lagging M**, Rembeck K, Waldenström J, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Hellstrand K. ITPA Variants are Associated with Reduced Relapse Rate but not with Early Virological Responses Following HCV Genotype 2/3 Therapy. *Hepatology*. 2014 Dec;60(6):2130-1. doi: 10.1002/hep.27108. **(Impact Factor 11.7)**
- 33) Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, Staffan Nilsson, Kristina Nyström, Anna Martner, Magnus Lindh, Court Pedersen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Kristine Mørch, Gunnar Norkrans, Peer Brehm Christensen, and **Martin Lagging**. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. *Hepatology*. 2014 Jun;59(6):2131-9. doi: 10.1002/hep.27009. **(Impact Factor 11.7)**
- 34) Jerkeman, Westin, **Lagging**, Norkrans, Lidman, Frimand, Simonsberg, Kakko, Widell, and Björkman. Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy – factors associated with advanced fibrosis. *Scand J Infect Dis*. 2014 May;46(5):340-7. doi: 10.3109/00365548.2013.879994. Epub 2014 Feb 20. **(Impact Factor 1.4)**

2013

- 35) Covolo L, Bibert S, Donato F, Bochud PY, **Lagging M**, Negro F, Fattovich G. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. *Aliment Pharmacol Ther*. 2013 Dec 5. doi: 10.1111/apt.12568. **(Impact Factor 6.3)**
- 36) Magdalena Ydreborg, Johan Westin, Karolina Rembeck, Magnus Lindh, Hans Norrgren, Anna Holmberg, Rune Wejstål, Gunnar Norkrans, Kristina Cardell, Ola Weiland, **Martin Lagging**. Impact of *IL28B*-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. *PLoS One*. 2013 Nov 14;8(11):e80172. doi: 10.1371/journal.pone.0080172. **(Impact Factor 3.5)**
- 37) **Martin Lagging**, Karolina Rembeck, Mads Rauning Buhl, Peer Christensen, Olav Dalgard, Martti Färkkilä, Kristoffer Hellstrand, Nina Langeland, Magnus Lindh, Johan Westin, and Gunnar Norkrans. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C infection genotype 2 or 3 with prior relapse. *Scandinavian Journal of Gastroenterology*. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389. **(Impact Factor 2.2)**
- 38) Jesper Waldenström, Jan Konar, Mats Olsson, Bengt Ekermo, Helene Norder, and **Martin Lagging**. Case report: neonatal transfusion-transmitted hepatitis c virus infection during the pre-seroconversion window-phase in a swedish blood donor. *Scand J Infect Dis*. 2013 Oct;45(10):796-9. doi: 10.3109/00365548.2013.797601. Epub 2013 Jun 9. **(Impact Factor 1.4)**
- 39) Lindh M, Arnholm B, Björkman P, Hellstrand K, **Lagging M**, Nilsson S, Wahlberg T, Wallmark E, Weiland O, Wejstål R, Westin J, Widell A, Norkrans G. Dynamic

tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin. *J Viral Hepat.* 2013 Apr;20(4):e82-e89. doi: 10.1111/jvh.12014. **(Impact Factor 4.2)**

- 40) Jonas Söderholm, Jesper Waldenström, Galia Askarieh, Massimo Pilli, Pierre-Yves Bochud, Francesco Negro, Jean-Michel Pawlotsky, Stefan Zeuzem, Carlo Ferrari, Gunnar Norkrans, Rune Wejstål, Johan Westin, Avidan U. Neumann, Bart L. Haagmans, Magnus Lindh, Gabriele Missale, Kristoffer Hellstrand, and **Martin Lagging**. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. *PLoS One.* 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. **(Impact Factor 3.5)**
- 41) Stéphanie Pascarella, Sophie Clément, Michael T. Dill, Stéphanie Conzelmann, **Martin Lagging**, Gabriele Missale, Avidan U. Neumann, Jean-Michel Pawlotsky, Stefan Zeuzem, Laura Rubbia-Brandt, Pierre-Yves Bochud, and Francesco Negro. Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. *Liver Int.* 2013 Jan;33(1):94-103. **(Impact Factor 4.5)**

2012

- 42) Karolina Rembeck, Cristina Maglio, **Martin Lagging**, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Gunnar Norkrans, Kristoffer Hellstrand, Magnus Lindh, Carlo Pirazzi, Maria Antonella Burza, Stefano Romeo, and Johan Westin. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. *BMC Med Genet.* 2012 Sep 14;13(1):82. **(Impact Factor 2.4)**
- 43) **Martin Lagging**. Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. *Pharmacogenomics.* 2012 Jun;13(8):847-9. **(Impact Factor 2.7)**
- 44) Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, **Lagging M**. Association between IL28B-related genetic variants and liver histopathology differs between HCV genotypes. *Hepatology.* 07/2012; 56(1):394. **(Impact Factor 11.7)**
- 45) Åsa Alsiö, Karolina Rembeck, Galia Askarieh, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Bart L. Haagmans, Salmir Nasic, Johan Westin, Kristoffer Hellstrand, Gunnar Norkrans, and **Martin Lagging**. Impact of obesity on the bioavailability of peginterferon- α 2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. *PLoS One.* 2012;7(5):e37521. **(Impact Factor 3.5)**
- 46) Karolina Rembeck, Åsa Alsiö, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Johan Westin, Magnus Lindh, Kristoffer Hellstrand, Gunnar Norkrans, and **Martin Lagging**. Impact of *IL28B*-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis c genotype 2 and 3. *PLoS One.* 2012;7(1):e29370. **(Impact Factor 3.5)**
- 47) Åsa Alsiö, Anna Jannesson, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Johan Westin, Kristoffer Hellstrand, Gunnar

Norkrans, and **Martin Lagging**. Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2/3 HCV infection. *Eur J Clin Microbiol Infect Dis*. 2012 Jul;31(7):1631-5. (**Impact Factor 2.9**)

48) Guedj H, Guedj J, Negro F, **Lagging M**, Westin J, Bochud PY, Bibert S, Neumann AU. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. *J Viral Hepat*. 2012 Jul;19(7):488-96 (**Impact Factor 4.2**)

49) **Lagging M**, Duberg AS, Wejstål R, Weiland O, Lindh M, Aleman S, Josephson F. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. *Scand J Infect Dis*. 2012 Jul;44(7):502-21 (**Impact Factor 1.4**)

50) Ydreborg M, Westin J, **Lagging M**, Castedal M, Friman S. Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience. *Scand J Gastroenterol*. 2012 Jun;47(6):710-7. (**Impact Factor 2.2**)

51) Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, **Lagging M**, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. *BMC Gastroenterol*. 2012 Jan 31;12:11. (**Impact Factor 2.7**)

2011

52) Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, **Lagging M**, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. *Liver Int*. 2011 Jul;31 Suppl 2:30-60. Review. (**Impact Factor 4.5**)

53) Alestig E, Arnholm B, Eilard A, **Lagging M**, Nilsson S, Norkrans G, Wahlberg T, Wejstål R, Westin J, Lindh M. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. *BMC Infect Dis*. 2011 May 12;11:124. (**Impact Factor 2.2**)

54) Giovanna Fattovich, Loredana Covolo, Stéphanie Bibert, Galia Askarieh, **Martin Lagging**, Sophie Clément, Giovanni Malerba, Michela Pasino, Maria Guido, Massimo Puoti, Giovanni Battista Gaeta, Teresa Santantonio, Giovanni Raimondo, Raffaele Bruno, Pierre-Yves Bochud, Francesco Donato, and Francesco Negro.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. *Aliment Pharmacol Ther.* 2011 May;33(10):1162-72. **(Impact Factor 6.3)**

- 55) Magdalena Ydreborg, Ann Söderström, Agneta Håkanson, Åsa Alsö, Birgitta Arnholm, Petter Malmström, Kristoffer Hellstrand, Johan Westin, and **Martin Lagging**. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. *Scand J Infect Dis.* 2011 Jul;43(6-7):522-7. **(Impact Factor 1.4)**
- 56) P.-Y. Bochud, S. Bibert, F. Negro, B. Haagmans, A. Soulier, C. Ferrari, G. Missale, S. Zeuzem, J.-M. Pawlotsky, S. Schalm, K. Hellstrand, A. U. Neumann, **M. Lagging**. *IL28B* polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. *J Hepatol.* 2011 Feb 24. **(Impact Factor 10.6)**
- 57) Lindh M, **Lagging M**, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K. *IL28B* polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. *J Viral Hepat.* 2011 Jul;18(7):e325-31. Epub 2011 Jan 13. **(Impact Factor 4.2)**
- 58) Magnus Lindh, **Martin Lagging**, Martti Färkkilä, Nina Langeland, Kristine Mørch, Staffan Nilsson, Gunnar Norkrans, Court Pedersen, Mads Rauning Buhl, Johan Westin, Kristoffer Hellstrand. *IL28B* variation at *rs12979860* determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. *J Infect Dis.* 2011 Jun;203(12):1748-52. **(Impact Factor 6.3)**
- 59) **Martin Lagging**, Galia Askarieh, Francesco Negro, Stephanie Bibert, Jonas Söderholm, Johan Westin, Magnus Lindh, Ana Romero, Gabriele Missale, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Bart L. Haagmans, Stefan Zeuzem, Pierre-Yves Bochud, and Kristoffer Hellstrand. Response prediction in chronic hepatitis C by assessment of IP-10 and *IL28B*-related single nucleotide polymorphisms. *PLoS One.* 2011 Feb 24;6(2):e17232. **(Impact Factor 3.5)**
- 60) **Martin Lagging**, Åsa Alsö, Kristoffer Hellstrand, and Gunnar Norkrans. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection? *J Hepatol.* 2011 Apr;54(4):835-6. **(Impact Factor 10.6)**
- 61) **Martin Lagging**, Åsa Alsö, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Kristoffer Hellstrand, and Gunnar Norkrans. Early determination of HCV RNA may help to decide the duration of therapy in chronic HCV genotype 2/3 infection. *Hepatology.* 2011 Mar;53(3):1067-8. **(Impact Factor 11.7)**
- 62) Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, **Lagging M**, Langeland N, Mørch K, Nilsson S, Pedersen C, Rauning Buhl M, Wahlberg T, Wejstål R, Westin J, and Norkrans G. Hepatitis C treatment response kinetics and impact of baseline predictors. *J Viral Hepat.* 2011 Jun;18(6):400-7. **(Impact Factor 4.2)**

- 63) Court Pedersen, Åsa Alsö, **Martin Lagging**, Nina Langeland, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Gunnar Norkrans and Peer Brehm Christensen. Ribavirin Plasma concentration Is A Predictor Of Sustained Virological Response In Patients treated 12 Or 24 Weeks With Peginterferon-alpha-2a And Ribavirin For Chronic Hepatitis C Virus Genotype 2 Or 3 infection. *J Viral Hepat.* 2011 Apr;18(4):245-251. **(Impact Factor 4.2)**
- 64) Westin J, Hellstrand K, Dhillon AP, **Lagging M.** Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C? *J Viral Hepat.* 2011 Feb;18(2):149-51. **(Impact Factor 4.2)**

2010

- 65) Magnus Lindh, **Martin Lagging**, Gunnar Norkrans, Kristoffer Hellstrand. Observed and calculated IL28B genotype frequencies in HCV infection. *Hepatology.* 2010 Nov;52(5):1860-1 **(Impact Factor 11.7)**
- 66) Magnus Lindh, **Martin Lagging**, Gunnar Norkrans, Kristoffer Hellstrand. A model explaining the correlation between *IL28B*-related genotypes, hepatitis C virus genotypes and viral RNA levels. *Gastroenterology.* 2010 Nov;139(5):1794-6. Epub 2010 Sep 29. **(Impact Factor 18.2)**
- 67) Karolin Falconer, Galia Askarieh, Nina Weis, Kristoffer Hellstrand, Annette Alaeus and **Martin Lagging.** IP-10 Predicts the First Phase Decline in HCV RNA and Overall Viral Response to Therapy in Chronic Hepatitis C Virus Infection in HIV Co-Infected Patients. *Scand J Infect Dis.* 2010 Dec;42(11-12):896-901. **(Impact Factor 1.4)**
- 68) Peter Leutscher, **Martin Lagging**, Mads R. Buhl, Court Pedersen, Åsa Alsö, Gunnar Norkrans, Nina Langenland, Martti Färkkilä, Simon Hjerrild, Kristoffer Hellstrand, and Per Bech. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. *Hepatology.* 2010 Aug;52(2):430-435. **(Impact Factor 11.7)**
- 69) Askarieh G, Alsö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, **Lagging M.** Systemic and intrahepatic interferon-gamma-inducible protein 10 predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. *Hepatology.* 2010 May;51(5):1523-30. **(Impact Factor 11.7)**
- 70) Åsa Alsö, Peer Christensen, Peter Leutscher Martti Färkkilä, Kristine Mørch, Bart Haagmans, Mads Rauning Buhl, Court Pedersen, Nina Langeland, Johan Westin, Kristoffer Hellstrand, Gunnar Norkrans, and **Martin Lagging.** Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations? *Clin Infect Dis.* 2010 Feb 15;50(4):e22-5. **(Impact Factor 8.7)**

2009

- 71) **Martin Lagging**, Rune Wejstål, Ingrid Uhnö, Barbro Gerdén, Björn Fischler, Styrbjörn Friman, Filip Josephson, Olle Karlström, Per Sangfelt, Robert Schwarz, and Ola Weiland for the Swedish Consensus Group. Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations. *Scand J Infect Dis.* 2009 Jul;41(6):389 – 402. **(Impact Factor 1.4)**

2008

- 72) **Martin Lagging**, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsö, Kristoffer Hellstrand, Johan Westin, Peer Christensen, Peter Leutscher, and Gunnar Norkrans for the NORDynamIC Study Group. Weight-adjusted dosing of ribavirin and importance of HCV RNA below 1000 IU/mL day 7 in short-term peg-interferon therapy for chronic genotype 2/3 HCV infection. *Hepatology*. 2008 Aug;48(2):695. (**Impact Factor 11.7**)
- 73) **Lagging M**, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsö A, Hellstrand K, Westin J, Norkrans G; NORDynamIC Study Group. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. *Hepatology*. 2008 Jun;47(6):1837-45. (**Impact Factor 11.7**)
- 74) **Martin Lagging**. Acute Exacerbation of Chronic Hepatitis B: Yet Another Incentive to Commence Universal Infant Immunization Even in Low Endemic Areas. *Scand J Gastroenterol*. 2008 Feb;43(2):131. (**Impact Factor 2.2**)
- 75) Westin J, Ydreborg M, Islam S, Alsio A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, **Lagging M**, Group FT. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. *Scand J Gastroenterol*. 2008 Jan;43(1):73-80. (**Impact Factor 2.2**)

2007

- 76) M. Pilli, A. Zerbini, A. Penna, A. Orlandini, E. Hagai, J.M. Pawlotsky, S. Zeuzem, S.W. Schalm, M. von Wagner, G. Germanidis, Y. Lurie, J.I. Esteban, B. Haagman, C. Hezode, **M. Lagging**, F. Negro, Y. Homburger, A.U. Neumann, C. Ferrari, G. Missale, for the DITTO-HCV Study Group. Role of the HCV-specific T cell response in relation to viral kinetics and treatment outcome in PEG-Interferon-alpha-2a and Ribavirin therapy (DITTO-HCV project) for chronic hepatitis C. *Gastroenterology*. 2007 Oct;133(4):1132-43. (**Impact Factor 12.8**)
- 77) Lindh M, Alestig E, Arnholm B, Eilard A, Hellstrand K, **Lagging M**, Wahlberg T, Wejstal R, Westin J, Norkrans G. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. *J Clin Microbiol*. 2007 Aug;45(8):2439-45. (**Impact Factor 4.0**)
- 78) Johan Westin, Kristoffer Hellstrand, Åsa Alsö, Magdalena Ydreborg, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Elke Verhey-Hart, **Martin Lagging**. Impact of Disease Severity on Outcome of Antiviral Therapy in Treatment Naïve Patients with Chronic Hepatitis C. *Hepatology*. 2007 May;45(5):1333-4. (**Impact Factor 11.7**)
- 79) Johan Westin, **Martin Lagging**, Amar P. Dhillon, Gunnar Norkrans, Ana Romero, Jean-Michel Pawlotsky, Stefan Zeuzem, Solko W. Schalm, Elke Verheij-Hart, Francesco Negro, Gabriele Missale, Avidan U. Neumann, Kristoffer Hellstrand for the DITTO-HCV Study Group. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. *J Viral Hepat*. 2007 Jan;14(1):29-35. (**Impact Factor 4.2**)

- 80) Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Bart J. Veldt, Bettina E. Hansen, Elke Verhey-Hart, **Martin Lagging**. Predicting Treatment Outcome Following 24 Weeks Peginterferon α -2a/Ribavirin Therapy in HCV Genotype 1 Infected Patients: Utility of HCV-RNA at Day 0, Day 22, Day 29 and Week 6. *Hepatology*. 2007 Jan;45(1):258-9. **(Impact Factor 11.7)**

2006

- 81) **Lagging M**, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. *Hepatology*. 2006 Dec;44(6):1617-25. **(Impact Factor 11.7)**
- 82) Romero AI, **Lagging M**, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Interferon (IFN)- gamma - Inducible Protein-10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN- alpha 2a and Ribavirin for Chronic Hepatitis C Virus Infection. *J Infect Dis*. 2006 Oct 1;194(7):895-903. **(Impact Factor 6.3)**
- 83) Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, **Lagging M**, Westin J, Schalm SW. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. *J Hepatol*. 2006 Oct;45(4):539-46. **(Impact Factor 10.6)**

2005

- 84) Islam S, Antonsson L, Westin J, **Lagging M**. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. *Scand J Gastroenterol*. 2005 Jul;40(7):867-72. **(Impact Factor 2.2)**
- 85) Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, **Lagging M**, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. *J Hepatol*. 2005 Aug;43(2):250-7. **(Impact Factor 10.6)**
- 86) Cavazza S, **Lagging M**. Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors. *Scand J Infect Dis*. 2005;37(6-7):488-92. **(Impact Factor 1.4)**
- 87) Lindh M, **Lagging M**, Westin J, Wejstal R, Norkrans G. Monitoring treatment response by the hepatitis C virus core antigen assay. *Eur J Clin Microbiol Infect Dis*. 2005 Mar;24(3):230-2. **(Impact Factor 2.9)**

2002

- 88) Westin J, Nordlinder H, **Lagging M**, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol.* 2002 Dec;37(6):837-42. (**Impact Factor 10.6**)
- 89) **L. Martin Lagging**, Clementina E. Garcia, Johan Westin, Rune Wejstål, Gunnar Norkrans, Amar P. Dhillon, Magnus Lindh. Comparison of serum HCV RNA and core antigen concentrations in Hepatitis C Virus infection, association with liver histology, and effect of storage time. *Journal of Clinical Microbiology*, 2002;40(11):4224-9. (**Impact Factor 3.6**)
- 90) **L. Martin Lagging**, Catarina Åneman, Nancy Nenonen, Åke Brandberg, Lars Grip, Gunnar Norkrans, and Magnus Lindh. Nosocomial Transmission of Hepatitis C Virus in a Cardiology Ward During the Window Phase of Infection: An Epidemiological and Molecular Investigation. *Scandinavian Journal of Infectious Diseases*, 2002;34(8):580-2. (**Impact Factor 1.7**)
- 91) Johan Westin, **L. Martin Lagging**, Fredrik Spak, Nibia Aires, Elisabeth Svensson, Magnus Lindh, Amar P. Dhillon, Gunnar Norkrans, Rune Wejstål. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. *Journal of Viral Hepatitis*, 2002;9(3):235-241. (**Impact Factor 4.2**)
- 92) **L. Martin Lagging**, Johan Westin, Elisabeth Svensson, Nibia Aires, Amar P. Dhillon, Magnus Lindh, Rune Wejstål, Gunnar Norkrans. Progression of Fibrosis in Untreated Patients with Hepatitis C Virus Infection. *Liver*, 2002;22(2):136-44. (**Impact Factor 4.5**)
- 93) **L. Martin Lagging**, Keith Meyer, Johan Westin, Rune Wejstål, Gunnar Norkrans, Magnus Lindh, Ranjit Ray. Neutralization of Pseudotyped VSV Expressing HCV E1 or E2 by Sera from Patients. *Journal of Infectious Diseases*, 2002;185(8):1165-9. (**Impact Factor 6.3**)
- 94) Keith Meyer, Arnab Basu, Craig T. Przysiecki, **L. Martin Lagging**, Adrian M. Di Bisceglie, Anthony J. Conley, Ranjit Ray. Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein. *Journal of Virology*, 2002;76(5):2150-8. (**Impact Factor 4.6**)

2001

- 95) Ranjit Ray, Daniel F. Hoft, Keith Meyer, Robin Brown, **L. Martin Lagging**, Robert B. Belshe. Immunoregulatory Role of Secreted Glycoprotein g from Respiratory Syncytial Virus. *Virus Research*, 2001;75(2):147-54. (**Impact Factor 2.5**)
- 96) Johan Westin, Magnus Lindh, Nancy Nenonen, **L. Martin Lagging**, Gunnar Norkrans, Rune Wejstål. Monitoring Virological Responses to Interferon-Ribavirin and Interferon Monotherapy of Chronic Hepatitis C Re-treated Due to Relapse or Non-Response. *Scandinavian Journal of Infectious Diseases* 2001;33(2):110-5. (**Impact Factor 1.7**)

1999

- 97) Johan Westin, Magnus Lindh, **L. Martin Lagging**, Gunnar Norkrans, and Rune Wejstål. Chronic Hepatitis C in Sweden: Genotype Distribution Over Time in

Different Epidemiological Settings. *Scandinavian Journal of Infectious Diseases*, 1999;31(4):355-358. **(Impact Factor 1.7)**

- 98) Johan Westin, **L. Martin Lagging**, Rune Wejstål, Gunnar Norkrans, Amar P. Dhillon. Interobserver Study of Liver Histopathology Using the Ishak Score in Patients with Chronic Hepatitis C Virus Infection. *Liver*, 1999;19(3):183-187. **(Impact Factor 4.5)**

1998

- 99) **L. Martin Lagging**, Keith Meyer, Randall J. Owens, Ranjit Ray. Functional Role of Hepatitis C Virus Chimeric Glycoproteins in Pseudotype Virus Infectivity. *Journal of Virology*, 1998;72(5):3539-3546. **(Impact Factor 4.6)**

1996

- 100) Ratna B. Ray, **L. Martin Lagging**, Keith Meyer, and Ranjit Ray. Hepatitis C Virus Core Protein Cooperates with *ras* and Transforms Primary Rat Embryo Fibroblasts to Tumorigenic Phenotype. *Journal of Virology*, 1996;70(7):4438-4443. **(Impact Factor 4.6)**

1995

- 101) **L. Martin Lagging**, Keith Meyer, Daniel Hoft, Michael Houghton, Robert B. Belshe, Ranjit Ray. Evaluation of Immune Responses to Plasmid DNA encoding the Hepatitis C Virus Core Protein. *Journal of Virology*, 1995;69(9):5859-5863. **(Impact Factor 4.6)**
- 102) Margarita Torralba, Sharon Frey, and **L. Martin Lagging**. Treatment of Methicillin Resistant *Staphylococcus aureus* Infection with Quinupristin/Dalfopristin. *Clinical Infectious Diseases*, 1995;21(2):460-461. **(Impact Factor 8.7)**
- 103) Ratna B. Ray, **L. Martin Lagging**, Keith Meyer, Steele R and Ranjit Ray. Transcriptional Regulation of Cellular and Viral Promoters by the Hepatitis C Virus Core Protein. *Virus Research*, 1995;37(3):209-220. **(Impact Factor 2.5)**

1994

- 104) Ranjit Ray, Aparna Khanna, **L. Martin Lagging**, Keith Meyer, Qui-Lim Choo, Robert Ralston, Michael Houghton, and Paul R. Becherer. Peptide Immunogen Mimicry of Putative E1 Glycoprotein Specific Epitopes in Hepatitis C Virus. *Journal of Virology*, 1994;68(7):4420-4426. **(Impact Factor 4.6)**
- 105) **L. Martin Lagging**, Clynie M. Breland, Donald J. Kennedy, Thomas W. Milligan, Marcia L. Sokol-Anderson, and T. Ulf Westblom. Delayed Treatment of Pulmonary Blastomycosis Causing Vertebral Osteomyelitis, Paraspinal Abscess, and Spinal Cord Compression. *Scandinavian Journal of Infectious Diseases* 1994;26(1):111-115. **(Impact Factor 1.7)**

1993

- 106) T. Ulf Westblom, **L. Martin Lagging**, Benteley R. Midkiff, and Steven J. Czinn. Evaluation of QuickVue, a Rapid Enzyme Immunoassay Test for the Detection of Serum Antibodies to *Helicobacter pylori*. *Diagnostic Microbiology and Infectious Diseases* 1993;16(4):317-320. **(Impact Factor 2.5)**

Ph D Thesis:

L. Martin Lagging. Hepatitis C Virus: Aspects on Natural History, Antibody Response, and Viral Quantification. June 2002. ISBN 91-628-5294-9.